IL266149B - קלציום קרבונט אמורפי לטיפול בלוקמיה - Google Patents
קלציום קרבונט אמורפי לטיפול בלוקמיהInfo
- Publication number
- IL266149B IL266149B IL266149A IL26614919A IL266149B IL 266149 B IL266149 B IL 266149B IL 266149 A IL266149 A IL 266149A IL 26614919 A IL26614919 A IL 26614919A IL 266149 B IL266149 B IL 266149B
- Authority
- IL
- Israel
- Prior art keywords
- composition
- acc
- acid
- leukemia
- stage
- Prior art date
Links
- 208000032839 leukemia Diseases 0.000 title claims description 61
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims description 46
- 238000011282 treatment Methods 0.000 title claims description 28
- 229910000019 calcium carbonate Inorganic materials 0.000 title claims description 25
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 87
- 239000000203 mixture Substances 0.000 claims description 82
- 239000003381 stabilizer Substances 0.000 claims description 75
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 63
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 58
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 58
- 230000000979 retarding effect Effects 0.000 claims description 31
- 229920000388 Polyphosphate Polymers 0.000 claims description 29
- 239000001205 polyphosphate Substances 0.000 claims description 29
- 235000011176 polyphosphates Nutrition 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 26
- 201000010099 disease Diseases 0.000 claims description 25
- 239000011575 calcium Substances 0.000 claims description 23
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 claims description 22
- 229950006137 dexfosfoserine Drugs 0.000 claims description 22
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 claims description 22
- 239000001226 triphosphate Substances 0.000 claims description 22
- 235000011178 triphosphate Nutrition 0.000 claims description 22
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 21
- 229940122361 Bisphosphonate Drugs 0.000 claims description 20
- 150000004663 bisphosphonates Chemical class 0.000 claims description 19
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 206010025280 Lymphocytosis Diseases 0.000 claims description 14
- 150000007524 organic acids Chemical class 0.000 claims description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 claims description 10
- 235000015872 dietary supplement Nutrition 0.000 claims description 10
- 150000002148 esters Chemical class 0.000 claims description 10
- 229960004585 etidronic acid Drugs 0.000 claims description 10
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 claims description 10
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 claims description 9
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 claims description 9
- 235000011180 diphosphates Nutrition 0.000 claims description 9
- 229940005740 hexametaphosphate Drugs 0.000 claims description 9
- 229960003074 medronic acid Drugs 0.000 claims description 9
- 239000002417 nutraceutical Substances 0.000 claims description 9
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 9
- 150000002894 organic compounds Chemical class 0.000 claims description 9
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 claims description 9
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 claims description 9
- 229960004276 zoledronic acid Drugs 0.000 claims description 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 8
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 8
- 210000000265 leukocyte Anatomy 0.000 claims description 8
- 239000011975 tartaric acid Substances 0.000 claims description 8
- 235000002906 tartaric acid Nutrition 0.000 claims description 8
- 229940062527 alendronate Drugs 0.000 claims description 6
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 6
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 3
- 125000004437 phosphorous atom Chemical group 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 description 24
- 150000003839 salts Chemical class 0.000 description 20
- 238000000034 method Methods 0.000 description 19
- 210000003743 erythrocyte Anatomy 0.000 description 15
- 210000001165 lymph node Anatomy 0.000 description 15
- 210000000952 spleen Anatomy 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 13
- 208000024207 chronic leukemia Diseases 0.000 description 12
- 210000004185 liver Anatomy 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 210000004698 lymphocyte Anatomy 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 206010000830 Acute leukaemia Diseases 0.000 description 8
- 229940048084 pyrophosphate Drugs 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 6
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 6
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 6
- 201000009277 hairy cell leukemia Diseases 0.000 description 6
- -1 phosphino, phosphono Chemical group 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 5
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 5
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 5
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 238000009534 blood test Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229910052708 sodium Inorganic materials 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 4
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 4
- 238000010009 beating Methods 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 229910052700 potassium Inorganic materials 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229960004343 alendronic acid Drugs 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 239000002105 nanoparticle Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- SJSQTARGNAQQKY-GBXIJSLDSA-N (2s,3r)-2-amino-3-sulfooxybutanoic acid Chemical compound OS(=O)(=O)O[C@H](C)[C@H](N)C(O)=O SJSQTARGNAQQKY-GBXIJSLDSA-N 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-L (R)-2-Hydroxy-3-(phosphonooxy)-propanal Natural products O=C[C@H](O)COP([O-])([O-])=O LXJXRIRHZLFYRP-VKHMYHEASA-L 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- XOHUEYCVLUUEJJ-UHFFFAOYSA-N 2,3-Bisphosphoglyceric acid Chemical compound OP(=O)(O)OC(C(=O)O)COP(O)(O)=O XOHUEYCVLUUEJJ-UHFFFAOYSA-N 0.000 description 2
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 description 2
- LXJXRIRHZLFYRP-VKHMYHEASA-N D-glyceraldehyde 3-phosphate Chemical compound O=C[C@H](O)COP(O)(O)=O LXJXRIRHZLFYRP-VKHMYHEASA-N 0.000 description 2
- 206010019842 Hepatomegaly Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- IMQLKJBTEOYOSI-GPIVLXJGSA-N Inositol-hexakisphosphate Chemical compound OP(O)(=O)O[C@H]1[C@H](OP(O)(O)=O)[C@@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@H](OP(O)(O)=O)[C@@H]1OP(O)(O)=O IMQLKJBTEOYOSI-GPIVLXJGSA-N 0.000 description 2
- LFZGUGJDVUUGLK-REOHCLBHSA-N L-serine O-sulfate Chemical compound OC(=O)[C@@H](N)COS(O)(=O)=O LFZGUGJDVUUGLK-REOHCLBHSA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 2
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Phytic acid Natural products OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 2
- 206010041660 Splenomegaly Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 2
- 229950006790 adenosine phosphate Drugs 0.000 description 2
- 229960001456 adenosine triphosphate Drugs 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 208000022532 enlargement of lymph nodes Diseases 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910001410 inorganic ion Inorganic materials 0.000 description 2
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 229910052748 manganese Inorganic materials 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 150000002482 oligosaccharides Polymers 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 2
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 2
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 2
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 2
- 239000000467 phytic acid Substances 0.000 description 2
- 235000002949 phytic acid Nutrition 0.000 description 2
- 229940068041 phytic acid Drugs 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011164 primary particle Substances 0.000 description 2
- 239000011163 secondary particle Substances 0.000 description 2
- BWAUQTFFVCLSOS-UHFFFAOYSA-N sodiosodium hydrate Chemical compound O.[Na].[Na] BWAUQTFFVCLSOS-UHFFFAOYSA-N 0.000 description 2
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 2
- 229940048086 sodium pyrophosphate Drugs 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000019832 sodium triphosphate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- XVOUMQNXTGKGMA-OWOJBTEDSA-N (E)-glutaconic acid Chemical compound OC(=O)C\C=C\C(O)=O XVOUMQNXTGKGMA-OWOJBTEDSA-N 0.000 description 1
- 239000001124 (E)-prop-1-ene-1,2,3-tricarboxylic acid Substances 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- LBTABPSJONFLPO-UHFFFAOYSA-N 2-amino-3-phosphonopropanoic acid Chemical compound OC(=O)C(N)CP(O)(O)=O LBTABPSJONFLPO-UHFFFAOYSA-N 0.000 description 1
- MAZUXGSAOIEIIG-UHFFFAOYSA-N 2-hydroxyimino-1-pyridin-3-ylethanone Chemical compound ON=CC(=O)C1=CC=CN=C1 MAZUXGSAOIEIIG-UHFFFAOYSA-N 0.000 description 1
- OSJPPGNTCRNQQC-REOHCLBHSA-N 3-phosphoglyceric acid Chemical class OC(=O)[C@@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-REOHCLBHSA-N 0.000 description 1
- PQGCEDQWHSBAJP-AIHAYLRMSA-N 5-O-phosphono-beta-D-ribofuranosyl diphosphate Chemical compound O[C@H]1[C@@H](O)[C@H](OP(O)(=O)OP(O)(O)=O)O[C@@H]1COP(O)(O)=O PQGCEDQWHSBAJP-AIHAYLRMSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- ZAQJHHRNXZUBTE-UHFFFAOYSA-N D-threo-2-Pentulose Natural products OCC(O)C(O)C(=O)CO ZAQJHHRNXZUBTE-UHFFFAOYSA-N 0.000 description 1
- KKUKTXOBAWVSHC-UHFFFAOYSA-N Dimethylphosphate Chemical compound COP(O)(=O)OC KKUKTXOBAWVSHC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- IDCBOTIENDVCBQ-UHFFFAOYSA-N TEPP Chemical compound CCOP(=O)(OCC)OP(=O)(OCC)OCC IDCBOTIENDVCBQ-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- YDONNITUKPKTIG-UHFFFAOYSA-N [Nitrilotris(methylene)]trisphosphonic acid Chemical compound OP(O)(=O)CN(CP(O)(O)=O)CP(O)(O)=O YDONNITUKPKTIG-UHFFFAOYSA-N 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 229940091181 aconitic acid Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HXXFSFRBOHSIMQ-FPRJBGLDSA-N alpha-D-galactose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H]1O HXXFSFRBOHSIMQ-FPRJBGLDSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940093740 amino acid and derivative Drugs 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000001084 basket cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- GTZCVFVGUGFEME-IWQZZHSRSA-N cis-aconitic acid Chemical compound OC(=O)C\C(C(O)=O)=C\C(O)=O GTZCVFVGUGFEME-IWQZZHSRSA-N 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- XWDLNPWILOXKHK-ALUAXPQUSA-L disodium [(2R,3S)-2,3-dihydroxy-4-oxopentyl] phosphate Chemical compound [Na+].P(=O)([O-])([O-])OC[C@H]([C@@H](C(C)=O)O)O.[Na+] XWDLNPWILOXKHK-ALUAXPQUSA-L 0.000 description 1
- VQLXCAHGUGIEEL-FAOVPRGRSA-L disodium;[(2r,3r,4s,5r)-2,3,4,5-tetrahydroxy-6-oxohexyl] phosphate Chemical compound [Na+].[Na+].[O-]P(=O)([O-])OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O VQLXCAHGUGIEEL-FAOVPRGRSA-L 0.000 description 1
- NTBQNWBHIXNPRU-MSQVLRTGSA-L disodium;[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)[C@@H](O)[C@H]1O NTBQNWBHIXNPRU-MSQVLRTGSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000013505 freshwater Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 150000001261 hydroxy acids Chemical class 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- DWRVHDWKWKFSAI-UHFFFAOYSA-N methyl 3,4-difluorobenzoate Chemical compound COC(=O)C1=CC=C(F)C(F)=C1 DWRVHDWKWKFSAI-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 150000002903 organophosphorus compounds Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- HWGNBUXHKFFFIH-UHFFFAOYSA-I pentasodium;[oxido(phosphonatooxy)phosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O HWGNBUXHKFFFIH-UHFFFAOYSA-I 0.000 description 1
- 229950007002 phosphocreatine Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
- MHXGNUVRVJWHJK-UHFFFAOYSA-N phosphono dihydrogen phosphate;sodium Chemical compound [Na].OP(O)(=O)OP(O)(O)=O MHXGNUVRVJWHJK-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- OQZCJRJRGMMSGK-UHFFFAOYSA-M potassium metaphosphate Chemical compound [K+].[O-]P(=O)=O OQZCJRJRGMMSGK-UHFFFAOYSA-M 0.000 description 1
- 235000019828 potassium polyphosphate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 235000019982 sodium hexametaphosphate Nutrition 0.000 description 1
- GCLGEJMYGQKIIW-UHFFFAOYSA-H sodium hexametaphosphate Chemical compound [Na]OP1(=O)OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])OP(=O)(O[Na])O1 GCLGEJMYGQKIIW-UHFFFAOYSA-H 0.000 description 1
- 235000019830 sodium polyphosphate Nutrition 0.000 description 1
- ODFAPIRLUPAQCQ-UHFFFAOYSA-M sodium stearoyl lactylate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC(=O)OC(C)C(=O)OC(C)C([O-])=O ODFAPIRLUPAQCQ-UHFFFAOYSA-M 0.000 description 1
- 229940080352 sodium stearoyl lactylate Drugs 0.000 description 1
- YEQQMAFLJISSCR-UHFFFAOYSA-M sodium;1-carboxyethenyl hydrogen phosphate;hydrate Chemical compound O.[Na+].OC(=O)C(=C)OP(O)([O-])=O YEQQMAFLJISSCR-UHFFFAOYSA-M 0.000 description 1
- LXLBEOAZMZAZND-UHFFFAOYSA-M sodium;hydroxy-[1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl]phosphinate Chemical compound [Na+].CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)([O-])=O LXLBEOAZMZAZND-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000213 sulfino group Chemical group [H]OS(*)=O 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- GTZCVFVGUGFEME-UHFFFAOYSA-N trans-aconitic acid Natural products OC(=O)CC(C(O)=O)=CC(O)=O GTZCVFVGUGFEME-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 150000003628 tricarboxylic acids Chemical class 0.000 description 1
- WVLBCYQITXONBZ-UHFFFAOYSA-N trimethyl phosphate Chemical compound COP(=O)(OC)OC WVLBCYQITXONBZ-UHFFFAOYSA-N 0.000 description 1
- 125000002264 triphosphate group Chemical group [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-I triphosphate(5-) Chemical compound [O-]P([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O UNXRWKVEANCORM-UHFFFAOYSA-I 0.000 description 1
- 150000004043 trisaccharides Chemical class 0.000 description 1
- KWEUUBDPVVHQAL-MSQVLRTGSA-K trisodium;[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-oxidophosphoryl] phosphate Chemical compound [Na+].[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O KWEUUBDPVVHQAL-MSQVLRTGSA-K 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/10—Carbonates; Bicarbonates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662412300P | 2016-10-25 | 2016-10-25 | |
| PCT/IL2017/051160 WO2018078616A1 (en) | 2016-10-25 | 2017-10-23 | Amorphous calcium carbonate for treating a leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL266149A IL266149A (he) | 2019-06-30 |
| IL266149B true IL266149B (he) | 2022-08-01 |
Family
ID=62024452
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL266149A IL266149B (he) | 2016-10-25 | 2017-10-23 | קלציום קרבונט אמורפי לטיפול בלוקמיה |
| IL294615A IL294615A (he) | 2016-10-25 | 2017-10-23 | קלציום קרבונט אמורפי לטיפול בלוקמיה |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL294615A IL294615A (he) | 2016-10-25 | 2017-10-23 | קלציום קרבונט אמורפי לטיפול בלוקמיה |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US11052108B2 (he) |
| EP (1) | EP3532074B1 (he) |
| JP (1) | JP7152785B2 (he) |
| KR (1) | KR102531595B1 (he) |
| CN (2) | CN110121351A (he) |
| AU (1) | AU2017349921B2 (he) |
| IL (2) | IL266149B (he) |
| WO (1) | WO2018078616A1 (he) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022000947A (es) | 2019-07-23 | 2022-04-26 | Amorphical Ltd | Carbonato de calcio amorfo para mejorar el rendimiento deportivo. |
| BR112022018055A2 (pt) * | 2020-03-11 | 2022-10-18 | Amorphical Ltd | Carbonato de cálcio amorfo para tratamento de acidose. |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008041236A2 (en) * | 2006-10-05 | 2008-04-10 | Ben-Gurion University Of The Negev Research And Development Authority | Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| WO2009053967A1 (en) * | 2007-10-22 | 2009-04-30 | Amorphical Ltd. | Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins |
| WO2014122658A1 (en) * | 2013-02-11 | 2014-08-14 | Amorphical Ltd. | Amorphous calcium carbonate for accelerated bone growth |
Family Cites Families (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4237147A (en) | 1974-01-04 | 1980-12-02 | Monsanto Company | Stabilized amorphous calcium carbonate |
| US4199496A (en) | 1974-09-05 | 1980-04-22 | Johnson Edwin L | Process for the recovery of chemicals from the shells of crustacea |
| DE3069953D1 (en) | 1980-11-21 | 1985-02-21 | Monsanto Co | Concentrates for the preparation of carbonated beverages |
| US4964894A (en) | 1986-03-31 | 1990-10-23 | Freepons Donald E | Plant growth regulators derived from chitin |
| EP0304987B1 (en) | 1987-08-28 | 1992-11-11 | Norwich Eaton Pharmaceuticals, Inc. | Novel calcium supplements |
| CA1336328C (en) | 1988-04-11 | 1995-07-18 | Walter G. Leonard | Method of increasing bone density in humans |
| DE3853422T2 (de) | 1988-06-09 | 1995-10-26 | Innogenetics Nv | HIV-3-Retrovirus und seine Verwendung. |
| US5886012A (en) | 1989-03-22 | 1999-03-23 | Peter K. T. Pang | Method of treatment for disease associated with excessive PHF using combination therapy involving exogenous calcium and calcium channel blockers |
| US5037639A (en) | 1989-05-24 | 1991-08-06 | American Dental Association Health Foundation | Methods and compositions for mineralizing calcified tissues |
| US6348571B1 (en) | 1994-09-12 | 2002-02-19 | Northwestern University | Corticotropin release inhibiting factor and methods of using same |
| JPH099871A (ja) | 1995-07-03 | 1997-01-14 | Kita Nippon Shokuhin Kk | 菓 子 |
| WO1997024069A1 (en) | 1995-12-26 | 1997-07-10 | Holomed Aps | A method and system for generating an x-ray image |
| JPH10236957A (ja) | 1997-02-24 | 1998-09-08 | Bankaku Souhonpo:Kk | 骨粗鬆症の改善剤 |
| US20060165784A1 (en) | 1997-05-06 | 2006-07-27 | Zhao Jin R | Calcium supplement |
| SE9702401D0 (sv) | 1997-06-19 | 1997-06-19 | Astra Ab | Pharmaceutical use |
| US6569472B1 (en) | 2000-09-01 | 2003-05-27 | Wm. Wrigley Jr. Company | Coated chewing gum products containing antacid and method of making |
| US20030077604A1 (en) | 2000-10-27 | 2003-04-24 | Yongming Sun | Compositions and methods relating to breast specific genes and proteins |
| JP2002205947A (ja) | 2000-12-11 | 2002-07-23 | Chafflose Corporation | 水虫治療薬 |
| ES2295391T3 (es) | 2001-08-16 | 2008-04-16 | Cmp Therapeutics Limited | Microparticulas de quitina y sus usos medicos. |
| JP2003292453A (ja) | 2002-04-02 | 2003-10-15 | Asahi Kasei Corp | 骨疾患治療用医薬複合剤 |
| JP2004081739A (ja) | 2002-08-29 | 2004-03-18 | Mitsuru Akashi | ハイドロキシアパタイト−ポリマー複合材料の止血用組成物 |
| KR20020082813A (ko) | 2002-09-06 | 2002-10-31 | 한국지질자원연구원 | 에탄올-에틸렌 글리콜계에서의 탄산화 반응을 이용하여제조된 비정질 탄산칼슘의 후처리 방법 |
| AU2003271016A1 (en) | 2003-09-17 | 2005-04-06 | Bio-Wave Institute Of Suzhou Hi-Tech New District Corporation, Ltd. | Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| GB0324918D0 (en) | 2003-10-24 | 2003-11-26 | Glaxo Group Ltd | Composition |
| KR100561231B1 (ko) | 2004-05-18 | 2006-03-15 | 한국지질자원연구원 | 표면개질에 의한 비정질 탄산칼슘 제조방법 |
| ES2447747T3 (es) | 2004-05-26 | 2014-03-12 | Ben Gurion University Of The Negev Research And Development Authority | Composiciones administrables por vía oral que comprenden carbonato cálcico amorfo estable |
| AU2005296271A1 (en) | 2004-10-15 | 2006-04-27 | University Of Tennessee Research Foundation | Methods for inducing apoptosis in adipocytes |
| EP1827480B1 (en) | 2004-12-21 | 2016-11-09 | MUSC Foundation For Research Development | Compositions and methods for promoting wound healing and tissue regeneration |
| CN101090949B (zh) | 2004-12-22 | 2013-06-05 | 索尔维公司 | 碱土金属碳酸盐的耐酸粒子 |
| DE102005047807A1 (de) | 2005-06-04 | 2006-12-07 | Solvay Infra Bad Hönningen GmbH | Modifizierte Nanopartikel |
| US20070041506A1 (en) | 2005-08-22 | 2007-02-22 | Michelle Bottino | Digital sensor holder |
| GB0522045D0 (en) | 2005-10-28 | 2005-12-07 | Novartis Ag | Pharmaceutical compositions |
| CA2637616A1 (en) | 2006-01-19 | 2007-07-26 | Osteotech, Inc. | Injectable and moldable bone substitute materials |
| WO2009087553A1 (en) | 2008-01-02 | 2009-07-16 | Aurobindo Pharma Limited | Kits for administering bisphosphonates |
| CN101314031A (zh) | 2008-07-14 | 2008-12-03 | 王冰 | 一种改善骨营养的制剂 |
| WO2010045558A1 (en) | 2008-10-17 | 2010-04-22 | Fresenius Medical Care Holdings, Inc. | Method of determining a phosphorus binder dosage for a dialysis patient |
| JP2012517466A (ja) | 2009-02-12 | 2012-08-02 | アドゥロ・マテリアル・アクチボラゲット | 制御されたドラッグデリバリーのための生体分解性担体を含む組成物 |
| CN101580260B (zh) | 2009-05-31 | 2011-04-27 | 河南大学 | 一种微乳液法制备无定形碳酸钙的方法 |
| EP2598579B1 (de) | 2010-07-30 | 2024-09-11 | Schaefer Kalk GmbH & Co. KG | Kugelförmige, amorphe calciumcarbonat-teilchen |
| WO2012030664A1 (en) | 2010-08-30 | 2012-03-08 | Pulmatrix, Inc. | Dry powder formulations and methods for treating pulmonary diseases |
| CN102085356B (zh) | 2010-12-28 | 2013-02-27 | 北京同仁堂健康药业股份有限公司 | 一种用于增加骨密度的组合物及其制备方法 |
| US8936773B2 (en) | 2011-04-28 | 2015-01-20 | Calera Corporation | Methods and compositions using calcium carbonate and stabilizer |
| JP2015500333A (ja) * | 2011-12-13 | 2015-01-05 | アモーフィカル リミテッド． | カルシウム吸収不良及び代謝性骨障害を治療するための非晶質炭酸カルシウム |
| EP2882687B1 (en) | 2012-08-07 | 2018-10-10 | Amorphical Ltd. | Method for producing stabilized amorphous calcium carbonate |
| CN103663532B (zh) | 2013-12-21 | 2015-10-28 | 中国科学院上海硅酸盐研究所 | 一种制备无定形碳酸钙纳米球的方法 |
| CA2956048C (en) | 2014-07-31 | 2023-01-24 | Amorphical Ltd. | Encapsulated amorphous calcium carbonate compositions |
| AU2016273058B2 (en) | 2015-06-04 | 2021-05-20 | Amorphical Ltd. | Amorphous calcium carbonate stabilized with polyphosphates or bisphosphonates |
| KR102828392B1 (ko) | 2016-01-18 | 2025-07-02 | 아모피컬 리미티드 | 신경, 근육 및 불임 질환 또는 병증의 치료를 위한 안정화된 무정형 탄산칼슘 |
| AU2017210259B2 (en) | 2016-01-18 | 2022-11-03 | Amorphical Ltd. | Stabilized amorphous calcium carbonate as a supplement for cell culture media |
-
2017
- 2017-10-23 IL IL266149A patent/IL266149B/he unknown
- 2017-10-23 IL IL294615A patent/IL294615A/he unknown
- 2017-10-23 JP JP2019521063A patent/JP7152785B2/ja active Active
- 2017-10-23 CN CN201780080064.9A patent/CN110121351A/zh active Pending
- 2017-10-23 CN CN202210530126.4A patent/CN114948992A/zh active Pending
- 2017-10-23 US US16/343,463 patent/US11052108B2/en active Active
- 2017-10-23 EP EP17863623.9A patent/EP3532074B1/en active Active
- 2017-10-23 KR KR1020197014131A patent/KR102531595B1/ko active Active
- 2017-10-23 AU AU2017349921A patent/AU2017349921B2/en active Active
- 2017-10-23 WO PCT/IL2017/051160 patent/WO2018078616A1/en not_active Ceased
-
2021
- 2021-06-14 US US17/346,975 patent/US20210299165A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008041236A2 (en) * | 2006-10-05 | 2008-04-10 | Ben-Gurion University Of The Negev Research And Development Authority | Composition comprising crustacean gastrolith components, calcium carbonate and its use |
| WO2009053967A1 (en) * | 2007-10-22 | 2009-04-30 | Amorphical Ltd. | Stable amorphous calcium carbonate comprising phosphorylated amino acids, synthetic phosphorylated peptides, and gastrolith proteins |
| WO2014122658A1 (en) * | 2013-02-11 | 2014-08-14 | Amorphical Ltd. | Amorphous calcium carbonate for accelerated bone growth |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3532074C0 (en) | 2023-08-23 |
| WO2018078616A1 (en) | 2018-05-03 |
| KR20190073448A (ko) | 2019-06-26 |
| EP3532074A4 (en) | 2020-07-08 |
| JP7152785B2 (ja) | 2022-10-13 |
| US20190262391A1 (en) | 2019-08-29 |
| EP3532074A1 (en) | 2019-09-04 |
| EP3532074B1 (en) | 2023-08-23 |
| US11052108B2 (en) | 2021-07-06 |
| IL294615A (he) | 2022-09-01 |
| KR102531595B1 (ko) | 2023-05-11 |
| CN110121351A (zh) | 2019-08-13 |
| AU2017349921A1 (en) | 2019-06-06 |
| US20210299165A1 (en) | 2021-09-30 |
| IL266149A (he) | 2019-06-30 |
| AU2017349921B2 (en) | 2023-06-15 |
| CN114948992A (zh) | 2022-08-30 |
| JP2019532086A (ja) | 2019-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11033576B2 (en) | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration | |
| US20210299165A1 (en) | Amorphous calcium carbonate for treating a leukemia | |
| US12121538B2 (en) | Compositions of amorphous calcium carbonate for inhalation, sublingual or buccal administration | |
| HK40013235A (en) | Amorphous calcium carbonate for treating a leukemia | |
| CN115835871A (zh) | 用于治疗酸中毒的非晶碳酸钙 | |
| WO2024246896A1 (en) | Amorphous calcium carbonate for prevention and treatment of myocardial ischemia | |
| US20240018009A1 (en) | Particles comprising amorphous divalent metal carbonate | |
| BR112017026125B1 (pt) | Composição de carbonato de cálcio amorfo estabilizado, uso, repositório e inalador | |
| EP3563875A1 (en) | Radium for radionuclide therapy, in combination with calcium metabolism affecting treatment | |
| CA3144221A1 (en) | Amorphous calcium carbonate for improving athletic performance | |
| US20220226356A1 (en) | Composition and Concentrate for Use in Preparation of Dialysis Solution, Corresponding Dialysis Solution and Combinations Comprising Container | |
| SE470511B (sv) | Användning av inositolreisfosfat för beredning av läkemedel |